Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제50권5호
  • /
  • Pages.285-291
  • /
  • 2024
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지
DOI QR코드

DOI QR Code

Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases

  • Ra-yeon Kim (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry) ;
  • Sung ok Hong (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry) ;
  • Jae-woong Jung (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry) ;
  • Mu-hang Lee (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry) ;
  • Young-kee Lee (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry) ;
  • Yu-jin Jee (Department of Oral and Maxillofacial Surgery, Kyung Hee University Dental Hospital at Gangdong, Kyung Hee University College of Dentistry)
  • 투고 : 2024.06.24
  • 심사 : 2024.09.06
  • 발행 : 2024.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease that can lead to severe destruction of the jaw. As there is no standard protocol for treating MRONJ, various treatments have been studied. Teriparatide has been used as an adjunct therapy for MRONJ. However, its effectiveness has not been sufficiently demonstrated for use as a standard treatment for MRONJ. This study aimed to demonstrate the efficacy of teriparatide in treating MRONJ by presenting two successfully treated cases. Each patient received teriparatide therapy with surgical intervention. The appropriateness of teriparatide use was evaluated based on the patient's systemic condition, and the administration of teriparatide was supervised by a physician. Complete resolution of the lesion was observed clinically and radiographically in both patients. The first patient underwent implant placement at the lesion site. Due to its anabolic properties and ability to stimulate bone remodeling, teriparatide is an effective adjunctive pharmacological treatment for bone healing before and after surgery with associated beneficial effects on bone and mucosal healing.

키워드

참고문헌

  1. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 2022;80:920-43. https://doi.org/10.1016/j.joms.2022.02.008
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/s0278-2391(03)00720-1
  3. Canalis E. Management of endocrine disease: novel anabolic treatments for osteoporosis. Eur J Endocrinol 2018;178:R33-44. https://doi.org/10.1530/eje-17-0920
  4. Chen T, Wang Y, Hao Z, Hu Y, Li J. Parathyroid hormone and its related peptides in bone metabolism. Biochem Pharmacol 2021;192:114669. https://doi.org/10.1016/j.bcp.2021.114669
  5. de Souza Tolentino E, de Castro TF, Michellon FC, Passoni ACC, Ortega LJA, Iwaki LCV, et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: systematic review. Head Neck 2019;41:4209-28. https://doi.org/10.1002/hed.25944
  6. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573-80. https://doi.org/10.1016/j.joms.2006.10.076
  7. Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, et al. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int 2014;25:1625-32. https://doi.org/10.1007/s00198-014-2622-8
  8. Zushi Y, Takaoka K, Tamaoka J, Ueta M, Noguchi K, Kishimoto H. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent 2017;3:11. https://doi.org/10.1186/s40729-017-0074-6
  9. Choi SY, Yoon D, Kim KM, Kim SJ, Kim HY, Kim JW, et al. Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases. J Korean Assoc Oral Maxillofac Surg 2024;50:103-9. https://doi.org/10.5125/jkaoms.2024.50.2.103
  10. Kim KM, Kim S, Hwang H, Kim HY, Kim D, Park JH, et al. Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: a case-control study. Oral Dis 2024;30:3286-95. https://doi.org/10.1111/odi.14801
  11. Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol 2020;38:2971-80. https://doi.org/10.1200/jco.19.02192
  12. Adami G, Fassio A, Gatti D, Viapiana O, Benini C, Danila MI, et al. Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Ther Adv Musculoskelet Dis 2022;14:1759720X221083541. https://doi.org/10.1177/1759720x221083541
  13. Shim GJ, Ohe JY, Yoon YJ, Kwon YD, Kim DY. Current trends in adjuvant therapies for medication-related osteonecrosis of the jaw. Appl Sci 2022;12:4035. https://doi.org/10.3390/app12084035
  14. Dos Santos Ferreira L, Abreu LG, Calderipe CB, Martins MD, Schuch LF, Vasconcelos ACU. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int 2021;32:2449-59. https://doi.org/10.1007/s00198-021-06078-z
  15. Anabtawi M, Tweedale H, Mahmood H. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2021;50:501-10. https://doi.org/10.1016/j.ijom.2020.07.021
  16. Eli Lilly and Company. FORTEO (teriparatide injection) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration [cited 2024 May 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021318Orig1s056lbl.pdf
  17. Mohammad Ismail SH, Simatherai D, Peraba P, Bee BC, Wong HS, Yakob S. Teriparatide use in the treatment of severe hypocalcemia after kidney transplantation: a case report. Kidney Transplant Transplant Immunol 2023;8(3 Suppl):S395. https://doi.org/10.1016/j.ekir.2023.02.886
  18. Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus 2022;6:e10665. https://doi.org/10.1002/jbm4.10665
  19. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012;27:2429-37. https://doi.org/10.1002/jbmr.1768
  20. Burckhardt P, Faouzi M, Buclin T, Lamy O; The Swiss Denosumab Study Group. Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 2021;36:1717-28. https://doi.org/10.1002/jbmr.4335
  21. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. https://doi.org/10.1016/s0140-6736(15)61120-5
  22. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017;32:1291-6. https://doi.org/10.1002/jbmr.3110
  23. Ristow O, Ruckschloss T, Muller M, Berger M, Kargus S, Pautke C, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 2019;47:491-9. https://doi.org/10.1016/j.jcms.2018.12.014
  24. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016;374:254-62. https://doi.org/10.1056/nejmcp1513724